Company Filing History:
Years Active: 2003-2009
Title: Thomas J Jentsch: Innovator in Chloride and Potassium Channel Research
Introduction
Thomas J Jentsch is a prominent inventor based in Hamburg, Germany. He has made significant contributions to the field of neuroscience through his innovative research on chloride and potassium channels. With a total of 5 patents, Jentsch's work has paved the way for advancements in the treatment of various neurological diseases.
Latest Patents
One of Jentsch's latest patents is focused on an animal model and cell-line expressing modified chlorine channels. This invention relates to a test system for identifying and testing active compounds that influence synaptic transmission, which can be crucial for treating neuronal diseases. The invention also addresses the treatment of conditions such as osteoporosis, Paget's disease, and other nerve-related disorders. Additionally, it involves genetically modified non-human mammals that do not express certain chloride channels, which can be used for testing substances that inhibit these channels.
Another significant patent by Jentsch pertains to the potassium channel KCNQ5 and the sequences encoding it. This invention provides isolated polynucleotides that encode the KCNQ5 potassium channel subunit. It also includes transformed cells and transgenic animals that can be utilized for screening chemical compounds affecting these potassium channels.
Career Highlights
Throughout his career, Thomas J Jentsch has worked with notable organizations, including Neurosearch A/S and the University of Michigan. His research has been instrumental in advancing our understanding of ion channels and their implications in various medical conditions.
Collaborations
Jentsch has collaborated with several professionals in his field, including Friedhelm Hildebrandt, to further enhance the impact of his research.
Conclusion
Thomas J Jentsch's innovative work in the field of chloride and potassium channels has led to significant advancements in neuroscience. His contributions continue to influence the development of treatments for various neurological diseases.